Our End User License Agreement has been updated. Click here to learn more

×

Benefits of Long-Term CGM

Eversense XL

Help Your Patients Maintain Tighter Control

  • Longer wear time

    92% industry-leading adherence across 3 pivotal trials.1-3

    Fully implantable 180-day sensor.

    Continuous readings and alerts around the clock.

    Greater insight

    Exceptional accuracy, especially in the 2.2-3.3 mmol/L range.1

    Charts, graphs and in-app reports to improve glycemic awareness.

    Three types of alerts (audio, on body vibe and mobile text) to guide safe management.

     

    Fewer obstacles

    No twice-monthly sensor replacement.

    Near-real time feedback to help predict and monitor trends.

    Detects 95% of hyper/hypo events in 15 minutes.1

     

    Improved self-management

    Exceptional 59-69% real-world time in target.1

Improved Real World Outcomes

Continuous Insights

Continuous Insights

Exceptional real-world time in target

59%-69% time in target4

Learn More
Long term

Long-Term Wear

Industry leading adherence

>23 hours of wear time1-3

Learn More
HbA1C

Improved Results

HbA1c reduction in pivotal studies1-3

0.5% HbA1c Reduction2

Learn More

Sign Up Your Patients Today

The Eversense XL long-term CGM System uniquely balances accuracy and discretion with an exceptional user experience.

Contact Us

1 Christiansen MP. PRECISION. Diabetes Technology & Therapeutics. Volume 21, Number 5, 2019. 2 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 3 Kropff J, Choudhary P, Neupane S, et al. PRECISE. Diabetes Care. 2017;40(1):63-68. 4 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 5 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 

MKT-001284 Rev1

Disclaimer

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

The Eversense®XL Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 180 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal is performed by a health care provider. The Eversense XL CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see global.eversensediabetes.com/safety-info.